Core Viewpoint - Ascentage Pharma Group International is actively participating in the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its commitment to addressing unmet medical needs in cancer through innovative therapies [1][2]. Company Overview - Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for cancer [3]. - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [3]. Key Products - The lead asset, Olverembatinib, is the first third-generation BCR-ABL1 inhibitor approved in China for treating chronic myeloid leukemia (CML) with T315I mutations and is included in the China National Reimbursement Drug List [4]. - Olverembatinib is currently undergoing a global registrational Phase III trial (POLARIS-2) for CML and additional trials for newly diagnosed Ph+ acute lymphoblastic leukemia (ALL) and SDH-deficient gastrointestinal stromal tumors (GIST) [4]. - The second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for hematologic malignancies, currently being commercialized in China for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [5]. - Lisaftoclax is involved in four global registrational Phase III trials, including studies in combination with BTK inhibitors and in newly diagnosed patients with various hematologic conditions [5]. Research and Development - Ascentage Pharma has established a robust R&D capability and holds a portfolio of global intellectual property rights [6]. - The company has formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer, as well as collaborations with prominent research institutions [6].

Core Insights - IN8bio has promoted Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately, to enhance leadership during a critical growth phase [1][2] Company Overview - IN8bio is a clinical-stage biopharmaceutical company focused on developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases [1][6] - The company's lead program, INB-100, targets acute myeloid leukemia, while other programs include INB-200 and INB-400 for glioblastoma, and INB-600 for oncology and autoimmune indications [6] Leadership and Experience - Dr. Rochlin has over 17 years of experience in biotechnology, including roles in scientific research, intellectual property, business development, and clinical manufacturing [3] - Prior to her role at IN8bio, she served as Chief Business Officer at Curadigm, contributing to the company's spin-out from Nanobiotix [3] Clinical Advancements - Under Dr. Rochlin's leadership, IN8bio has advanced its clinical programs, including the development of INB-619, which has shown promising preclinical results in achieving complete B cell depletion with minimal adverse effects [4] - The company has made significant progress in its clinical manufacturing program, supporting multiple Phase 1 and 2 clinical trials in glioblastoma and hematological cancers [4] Future Outlook - Dr. Rochlin expressed confidence in the company's position to build on momentum from encouraging clinical data and aims to execute corporate priorities for long-term success [5]

Core Insights - Oryzon Genomics has initiated a Phase Ib trial for iadademstat, a selective LSD1 inhibitor, in combination with radiotherapy and an immune checkpoint inhibitor for extensive stage small cell lung cancer (ES-SCLC) patients [1][2][3] Group 1: Trial Details - The trial, titled "Iadademstat and Radiation Therapy With Atezolizumab in Extensive Stage Small-cell Lung Cancer (ES-SCLC) Patients With Persistent, Recurrent or Progressive Disease After First Line Systemic Therapy," is an open-label, non-randomized study [2] - It will evaluate the safety, tolerability, and efficacy of iadademstat combined with atezolizumab and stereotactic body radiation therapy (SBRT) [2] - The study will enroll patients who have previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy [2] Group 2: Company Overview - Oryzon Genomics, founded in 2000 in Barcelona, Spain, is a clinical-stage biopharmaceutical company focused on epigenetics and personalized medicine in CNS disorders and oncology [4] - The company has a clinical portfolio that includes two LSD1 inhibitors: vafidemstat (Phase III-ready) and iadademstat (Phase II) [4] - Oryzon is also developing other pipeline assets targeting different epigenetic mechanisms, including HDAC-6 [4] Group 3: Iadademstat Profile - Iadademstat (ORY-1001) is a small oral molecule that selectively inhibits the epigenetic enzyme LSD1, showing promising results in hematologic cancers [5] - Previous trials have demonstrated its safety and preliminary antileukemic activity, with encouraging results in combination with azacitidine [5] - The drug is currently being evaluated in various studies, including combinations with azacitidine and venetoclax in first-line acute myeloid leukemia (AML) [5][7] Group 4: Research and Development Focus - The combination of LSD1 inhibition with immunotherapy and radiotherapy is seen as a compelling strategy for treating aggressive cancers like SCLC [3] - Oryzon is expanding iadademstat's clinical development into non-oncological hematology indications, with trials in sickle cell disease and essential thrombocythemia [7] - Iadademstat has received orphan drug designation for SCLC and AML in both the US and EU [7]

Core Insights - 4D Molecular Therapeutics has completed enrollment for the 4FRONT-1 Phase 3 clinical trial of 4D-150 in patients with wet age-related macular degeneration (wet AMD) [1][4] - The trial achieved enrollment in approximately 11 months, exceeding initial projections and reflecting strong interest from both investigators and patients [2][4] - Topline data from the 4FRONT-1 trial is expected in the first half of 2027, with a second Phase 3 trial, 4FRONT-2, on track for completion in the second half of 2026 [4] Company Overview - 4D Molecular Therapeutics is a late-stage biotechnology company focused on developing durable and disease-targeted therapeutics, particularly for retinal diseases [7] - The lead product candidate, 4D-150, aims to provide sustained delivery of anti-VEGF biologics through a single intravitreal injection, potentially reducing the treatment burden for patients [5][7] - The company is also developing 4D-710, a genetic medicine for cystic fibrosis, demonstrating its commitment to innovative therapeutic solutions [7] Clinical Trial Details - The 4FRONT-1 trial is a multicenter, randomized, double-masked study comparing intravitreal 4D-150 to aflibercept, with the primary endpoint being non-inferiority in best corrected visual acuity (BCVA) at 52 weeks [2][4] - The trial is specifically targeting treatment-naïve wet AMD patients across North America, with plans for supplemental aflibercept injections for participants [2][4] - The second Phase 3 trial, 4FRONT-2, will include both treatment-naïve and recently diagnosed treatment-experienced patients, with an identical design to 4FRONT-1 [4] Market Context - Wet AMD is a prevalent condition, with over 4 million individuals expected to be affected in major markets within the next five years, and 200,000 new diagnoses annually in the U.S. [6] - The disease is characterized by abnormal blood vessel growth in the retina, leading to vision loss, which underscores the need for effective treatment options [6]

Core Insights - Veradermics has completed enrollment in its second Phase 3 clinical trial for VDPHL01, a treatment for male pattern hair loss, marking a significant milestone in the development of this innovative therapy [1][3] Company Overview - Veradermics is a late clinical-stage biopharmaceutical company founded by dermatologists, focusing on developing therapeutics for aesthetic and dermatological conditions [5] - The company aims to create a portfolio of products targeting high-prevalence dermatologic conditions, with VDPHL01 being its lead program for treating pattern hair loss [5][6] Product Details - VDPHL01 is an oral, extended-release formulation of minoxidil designed to enhance hair restoration while minimizing cardiac side effects [2][6] - The proprietary formulation uses a gel matrix for a steady release of minoxidil, aiming for consistent hair growth without exceeding cardiac activity thresholds [2][6] Clinical Trials - The completed Phase 3 male trial, named '304', involved 536 participants and evaluated the safety and efficacy of VDPHL01 over 52 weeks [3] - The co-primary endpoints of the trial include changes in non-vellus hair count and patient-reported hair coverage benefits at 24 weeks [3] - Veradermics anticipates topline data from its first Phase 2/3 trial in males in the first half of 2026 [4] Market Context - Pattern hair loss affects approximately 80 million people in the U.S., with a significant impact on quality of life, including mental health issues [8] - There have been no new FDA-approved treatments for pattern hair loss in nearly 30 years, highlighting a substantial market opportunity for innovative therapies like VDPHL01 [8] - The market for pattern hair loss treatments is projected to reach around $30 billion by 2028, driven by high demand for effective solutions [8]

Core Viewpoint - Anavex Life Sciences Corp. is advancing its clinical pipeline, particularly focusing on its lead candidate, oral blarcamesine, for early Alzheimer's disease, with a commitment to improving the lives of patients with neurological disorders [2][3]. Financial Highlights - Cash and cash equivalents increased to $131.7 million as of December 31, 2025, compared to $102.6 million at September 30, 2025, indicating a cash runway of more than 3 years at the current utilization rate [11]. - Research and development expenses for the quarter were $4.7 million, down from $10.4 million in the comparable quarter of fiscal 2025 [11]. - General and administrative expenses decreased to $2.1 million from $3.1 million in the same period last year [11]. - The net loss for the quarter was $5.7 million, or $0.06 per share, compared to a net loss of $12.1 million, or $0.14 per share for the comparable fourth quarter of fiscal 2025 [11]. Recent Corporate Developments - Anavex is making progress on its clinical development program for Parkinson's disease and has updates on regulatory pathways for blarcamesine in both early Alzheimer's disease and Rett syndrome [6]. - The company announced its participation in ACCESS-AD, a European initiative aimed at accelerating innovative diagnostic and therapeutic approaches for Alzheimer's disease [6]. - Wolfgang Liedtke, MD PhD, was appointed as Senior Vice President, Global Head of Neurology, bringing over 25 years of experience in CNS diseases [6]. Expected Development Milestones - Upcoming presentations include an oral presentation at the 16th Intrinsic Capacity, Frailty and Sarcopenia Research Conference, focusing on the treatment of older adults with pre-frailty using oral blarcamesine [6]. - Anavex plans to submit existing data from the Phase IIb/III ANAVEX2-73-AD-004 program to the FDA to support a New Drug Application for Alzheimer's disease [11].

Core Insights - Cytokinetics has awarded grants to two patient advocacy organizations to enhance communication and community outreach for hypertrophic cardiomyopathy (HCM) [2][3] Group 1: Grant Recipients and Initiatives - Camp Taylor received a grant to produce "Living with HCM: Youth Voices from Camp Taylor," a digital initiative that includes a five-part video series and an information toolkit aimed at educating families about HCM [4] - The Canadian Sudden Arrhythmia Death Syndromes (SADS) Foundation will develop "Think. Know. Act.: Cardiomyopathy Awareness in Canada," a six-month digital campaign to raise awareness of HCM symptoms and management among Canadian families [5] Group 2: Purpose and Impact of the Grant Program - The Cytokinetics Communications Grant Program aims to support patient advocacy organizations by providing resources for communications and outreach initiatives that are otherwise difficult to implement [6] - The program has been active for eight years, focusing on increasing awareness and community engagement for patient communities [6] Group 3: Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology and a pipeline of potential new medicines for cardiac muscle dysfunction [7] - The company’s product MYQORZO™ (aficamten) is approved for treating adults with symptomatic obstructive HCM, with positive opinions for marketing authorization in the European Union expected in early 2026 [7][8]

Core Viewpoint - BeyondSpring Inc. is participating in the Immuno-Oncology 360° Conference 2026 to present its innovative cancer therapy, Plinabulin, which aims to enhance PD-1/PD-L1 blockade and address resistance in cancer treatment [1][2]. Company Overview - BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for high unmet medical needs, with its lead asset, Plinabulin, in late-stage clinical development for non-small cell lung cancer (NSCLC) and other indications [4]. Presentation Details - Dr. Lan Huang, Co-Founder, Chairman, and CEO, will present on the topic "Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin" on February 11, 2026, from 4:55 PM to 5:10 PM ET at the Sheraton Boston Hotel [3]. - The presentation will be part of the Translational Science & Biomarkers track, focusing on expanding therapeutic horizons [3]. - Following the presentation, slides will be available on the company's website [3]. Mechanism of Action - Plinabulin operates as a dendritic cell maturation agent, which supports both anti-cancer activity and immune modulation, providing a unique approach to resensitizing tumors that are resistant to checkpoint inhibitors [4].

Core Insights - Obexelimab demonstrated a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo in the Phase 2 MoonStone trial, indicating significant efficacy in treating Relapsing Multiple Sclerosis (RMS) [1][2] - The 24-week data further confirmed the drug's robust and durable activity, maintaining significant reductions in lesions and improving biomarkers associated with disease activity [3][4] - The safety profile of obexelimab was consistent with previous trials, showing good tolerability without new safety signals [2][3] Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [12] - The company is advancing two late-stage product candidates: obexelimab and orelabrutinib, with obexelimab being the lead candidate targeting B cell activity [12] - Zenas plans to submit a Biologics License Application (BLA) for obexelimab in the second quarter of 2026 and a Marketing Authorization Application (MAA) in the second half of 2026 for Immunoglobulin G4-Related Disease [11][12] Clinical Trial Details - The Phase 2 MoonStone trial enrolled 116 patients and was designed to evaluate the efficacy and safety of obexelimab in RMS, using MRI endpoints to measure treatment outcomes [9] - The trial's primary endpoint was the cumulative number of new gad-enhancing T1 lesions over weeks 8 and 12, with secondary endpoints assessing disease progression through various biomarkers [9] - Following the double-blind phase, patients transitioned to an open-label period to continue treatment and assess long-term outcomes [9] Mechanism of Action - Obexelimab is a bifunctional monoclonal antibody that binds to CD19 and FcγRIIb, inhibiting B cell activity without depleting them, which is crucial for addressing autoimmune diseases [10][12] - The drug's unique mechanism and self-administered subcutaneous injection regimen may effectively target the pathogenic role of B cells in chronic autoimmune conditions [10][12]

VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced its Board of Directors has unanimously appointed Adam Rogers, MD, as President and Chief Executive Officer (CEO), effective immediately. Dr. Rogers will continue leading the C ...